- Home
- SGA vs MNOV Comparison
SGA vs MNOV Comparison
Compare SGA & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGA | MNOV |
|---|---|---|
| Founded | 1986 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.7M | 69.4M |
| IPO Year | 1994 | 2004 |
Fundamental Metrics
Financial Performance| Metric | SGA | MNOV |
|---|---|---|
| Price | $10.95 | $1.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 7.6K | ★ 21.8K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | ★ 9.05% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $124,829,000.00 | $2,360,807.00 |
| Revenue This Year | $6.74 | N/A |
| Revenue Next Year | N/A | $180.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 5.65 | ★ 194.15 |
| 52 Week Low | $10.68 | $1.17 |
| 52 Week High | $14.27 | $1.96 |
Technical Indicators
Market Signals| Indicator | SGA | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 39.81 | 49.83 |
| Support Level | $10.68 | $1.40 |
| Resistance Level | $12.02 | $1.43 |
| Average True Range (ATR) | 0.35 | 0.04 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 21.20 | 37.71 |
Price Performance
Historical ComparisonAbout SGA Saga Communications Inc. (FL)
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.